Thermo Fisher Scientific is adding early development work for oral solid dose therapies to its Bourgoin, France site, enabling that location to provide early drug development through commercial manufacturing.        In addition to expanded good manufacturing practices (GMP) facilities, the early development hub includes a 4,600 sq.-ft. research and development facility for preclinical, non-GMP operations.      Bourgoin is a Thermo Fisher center of excellence in Europe for oral solid dose end...